First Personalized Gene Therapy Using Base Editing Shows Promising Results in Baby with Rare Disorder
- KJ Muldoon, a nine-and-a-half-month-old baby from Pennsylvania, received a custom gene-editing therapy to treat his rare CPS1 deficiency in 2024 at Children's Hospital of Philadelphia.
- Doctors developed the therapy within seven months using CRISPR to correct KJ's mutation because his condition caused toxic ammonia buildup and no effective treatments existed.
- After three doses, KJ's ammonia levels stabilized, he reduced nitrogen-scavenging medication, increased protein intake, gained weight, and showed no safety concerns, enabling plans for hospital discharge.
- The initial animal tests showed a 42% liver correction rate, and the FDA approved the investigational new drug within a week, highlighting unprecedented regulatory speed for a tailored gene therapy.
- This case demonstrates the potential of personalized gene editing to treat rare diseases, though KJ requires monitoring and may still need a liver transplant, while researchers envision broader applications ahead.
Insights by Ground AI
Does this summary seem wrong?
290 Articles
290 Articles
All
Left
56
Center
118
Right
27
Baby in the US becomes the first treated with personalized CRISPR Gene-Editing
In a groundbreaking advancement in genetic medicine, a baby in the United States has become the first person to be treated with a personalized CRISPR gene-editing therapy, marking a historic moment for science and the future of rare disease treatment. According to a report by ScienceAlert, the infant was born with a rare and deadly […]
Coverage Details
Total News Sources290
Leaning Left56Leaning Right27Center118Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 28%
C 59%
13%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage